
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Gastroenterology</li><li>- <b>Publication Date:</b> 2023</li><li>- <b>Volume:</b> 164, Pages: 1086–1106</li><li>- <b>DOI:</b> https://doi.org/10.1053/j.gastro.2023.03.214</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended starting dose for prucalopride in adults with severe renal impairment (CrCl <30 mL/min)?</li><li>- What percentage of patients discontinued lubiprostone due to nausea in clinical trials?</li><li>- What is the typical onset of action for a bisacodyl rectal suppository?</li><li>- In the single RCT on senna, what percentage of participants reduced their daily dose during the trial?</li><li>- What is the recommended daily fiber intake by the Academy of Nutrition and Dietetics?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Executive Summary & Introduction</strong></summary>
            <div>
                <ul><li>- <b>Chronic Idiopathic Constipation (CIC)</b> is a common disorder of gut-brain interaction affecting <q>8%–12%</q> of the US population.</li><li>- Associated with infrequent/incomplete defecation without structural abnormalities.</li><li>- Medical costs are estimated between <q>$2,000 and $7,500</q> per patient per year.</li></ul>
                
        <details>
            <summary><strong>Initial Management</strong></summary>
            <div>
                <ul><li>- <u>Nonpharmacological therapies</u> are often the initial steps.</li><li>- Includes dietary changes (increased fluid and fiber) and behavioral changes (exercise).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fiber Supplementation</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 1:</b> <u>Suggests</u> the use of fiber supplementation over no supplements.</li><li>- <b>Strength:</b> Conditional</li><li>- <b>Certainty of Evidence:</b> Low</li></ul>
                
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- Can be used as <u>first-line therapy</u>, especially for individuals with low dietary fiber intake.</li><li>- Among evaluated supplements, only <b>psyllium</b> appears effective.</li><li>- <b>Flatulence</b> is a commonly observed side effect.</li><li>- The Academy of Nutrition and Dietetics recommends <q>14 g/1,000 kcal</q> intake per day.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Types of Fiber</strong></summary>
            <div>
                <ul><li>- <b>Soluble fiber:</b> Traps water, softens stool (e.g., psyllium, inulin, oats).</li><li>- <b>Insoluble fiber:</b> Increases stool bulk (e.g., wheat bran, methylcellulose).</li></ul>
                
        <details>
            <summary><strong>Bran</strong></summary>
            <div>
                <ul><li>- <b>Certainty of Evidence:</b> Very Low</li><li>- Based on one small crossover study (n=29).</li><li>- May increase Spontaneous Bowel Movements (SBMs) per week, but with a wide confidence interval (MD <q>1.30</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Inulin</strong></summary>
            <div>
                <ul><li>- <b>Certainty of Evidence:</b> Very Low to Low</li><li>- Had little to no effect on SBMs per week (MD <q>0.75</q>).</li><li>- A minor side effect of <b>flatulence</b> occurred more frequently in the inulin group.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Psyllium</strong></summary>
            <div>
                <ul><li>- <b>Certainty of Evidence:</b> Low</li><li>- May lead to an increase in SBMs per week (MD <q>2.32</q>).</li><li>- May increase global relief symptoms (RR <q>1.86</q>).</li><li>- Studied dose was <q>5 g twice daily</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Osmotic Laxatives</strong></summary>
            <div>
                <ul><li>- These agents work by creating an osmotic gradient, drawing water into the intestinal lumen.</li></ul>
                
        <details>
            <summary><strong>Polyethylene Glycol (PEG)</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 2:</b> <u>Recommends</u> the use of PEG.</li><li>- <b>Strength:</b> Strong</li><li>- <b>Certainty of Evidence:</b> Moderate</li></ul>
                
        <details>
            <summary><strong>Implementation & Dosing</strong></summary>
            <div>
                <ul><li>- Response to PEG has been shown to be durable over <q>6 months</q>.</li><li>- Standard dose is <q>17 g daily</q>.</li><li>- Side effects include abdominal distension, loose stool, flatulence, and nausea.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Likely results in an increase in Complete Spontaneous Bowel Movements (CSBMs) per week (MD <q>2.90</q>).</li><li>- Increases SBMs per week (MD <q>2.30</q>).</li><li>- Associated with a higher responder rate (RR <q>3.13</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Magnesium Oxide (MgO)</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 3:</b> <u>Suggests</u> the use of MgO.</li><li>- <b>Strength:</b> Conditional</li><li>- <b>Certainty of Evidence:</b> Very Low</li></ul>
                
        <details>
            <summary><strong>Implementation & Dosing</strong></summary>
            <div>
                <ul><li>- The panel suggests starting at a lower dose (e.g., <q>400–500 mg daily</q>).</li><li>- <u>Avoid use in patients with renal insufficiency</u> due to risk of <b>hypermagnesemia</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Studied dose was <q>1.5 g/d</q> for 4 weeks.</li><li>- May increase CSBMs per week (MD <q>4.29</q>) and SBMs per week (MD <q>3.59</q>).</li><li>- Achieved a higher treatment response compared to placebo (RR <q>3.93</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Lactulose</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 4:</b> <u>Suggests</u> use in adults who fail or are intolerant to other OTC therapies.</li><li>- <b>Strength:</b> Conditional</li><li>- <b>Certainty of Evidence:</b> Very Low</li></ul>
                
        <details>
            <summary><strong>Implementation & Dosing</strong></summary>
            <div>
                <ul><li>- <b>Bloating and flatulence</b> are dose-dependent and common side effects, which may limit its use.</li><li>- FDA-approved dose is <q>10–20 g (15–30 mL)</q> daily, may be increased to <q>40 g</q> daily.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- May have little to no effect on SBMs per week.</li><li>- May be associated with a large increase in global relief (RR <q>2.42</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Stimulant Laxatives</strong></summary>
            <div>
                <ul><li>- These agents stimulate colonic peristalsis and secretion.</li></ul>
                
        <details>
            <summary><strong>Bisacodyl or Sodium Picosulfate (SPS)</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 5:</b> <u>Recommends</u> use for <b>short-term</b> or as <b>rescue therapy</b>.</li><li>- <b>Strength:</b> Strong</li><li>- <b>Certainty of Evidence:</b> Moderate</li></ul>
                
        <details>
            <summary><strong>Implementation & Dosing</strong></summary>
            <div>
                <ul><li>- Short-term use is defined as daily use for <q>4 weeks or less</q>.</li><li>- Common side effects: abdominal pain, cramping, diarrhea.</li><li>- Panel suggests starting at a lower dose (e.g., <q>5 mg</q> orally).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Mechanism & Onset</strong></summary>
            <div>
                <ul><li>- Both are converted to the same active metabolite, <b>BHPM</b>.</li><li>- Onset of action: <q>6–12 hours</q> for oral tablet, <q>30–60 minutes</q> for rectal suppository.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Leads to a large increase in CSBMs per week (MD <q>2.54</q>) and SBMs per week (MD <q>4.04</q>).</li><li>- Higher responder rates (RR <q>2.60</q>).</li><li>- May increase diarrhea compared to placebo (RR <q>8.76</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Senna</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 6:</b> <u>Suggests</u> the use of senna.</li><li>- <b>Strength:</b> Conditional</li><li>- <b>Certainty of Evidence:</b> Low</li></ul>
                
        <details>
            <summary><strong>Implementation & Dosing</strong></summary>
            <div>
                <ul><li>- The dose evaluated in the single trial (<q>1 g</q>) is higher than commonly used doses.</li><li>- Panel suggests starting at a lower dose.</li><li>- Abdominal pain and cramping may occur with higher doses.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Based on one placebo-controlled RCT.</li><li>- Participants had higher CSBMs per week (MD <q>7.60</q>) and SBMs per week (MD <q>7.6</q>).</li><li>- Response rate was higher in the senna group (RR <q>5.25</q>).</li><li>- Notably, <q>83%</q> of participants randomized to senna reduced their daily dose during the trial.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Secretagogues</strong></summary>
            <div>
                <ul><li>- These agents increase intestinal fluid secretion, accelerating GI transit.</li><li>- Recommended for patients who do not respond to OTC agents.</li></ul>
                
        <details>
            <summary><strong>Lubiprostone</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 7:</b> <u>Suggests</u> the use of lubiprostone.</li><li>- <b>Strength:</b> Conditional</li><li>- <b>Certainty of Evidence:</b> Low</li></ul>
                
        <details>
            <summary><strong>Mechanism & Dosing</strong></summary>
            <div>
                <ul><li>- Acts on <b>chloride channel type 2</b>.</li><li>- Dose for CIC: <q>24 mg BID</q>.</li><li>- Dose for IBS-C: <q>8 mg BID</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation & Side Effects</strong></summary>
            <div>
                <ul><li>- <b>Nausea</b> is the most common adverse event, observed in <q>35%</q> of individuals.</li><li>- Nausea led to discontinuation of therapy in only <q>5%</q> of individuals.</li><li>- Risk of nausea is dose-dependent and lower when taken with food and water.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Resulted in an increased number of SBMs per week (MD <q>1.98</q>).</li><li>- May increase responder rates (RR <q>1.67</q>).</li><li>- Increased risk of diarrhea leading to discontinuation (RR <q>5.30</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Linaclotide</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 8:</b> <u>Recommends</u> the use of linaclotide.</li><li>- <b>Strength:</b> Strong</li><li>- <b>Certainty of Evidence:</b> Moderate</li></ul>
                
        <details>
            <summary><strong>Mechanism & Dosing</strong></summary>
            <div>
                <ul><li>- Acts on <b>guanylate cyclase-C</b>.</li><li>- Dose for CIC: <q>72 mg or 145 mg</q> daily.</li><li>- Dose for IBS-C: <q>290 mg</q> daily.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation & Side Effects</strong></summary>
            <div>
                <ul><li>- Should be taken <q>at least 30 minutes before</q> the first meal of the day.</li><li>- May be associated with diarrhea leading to discontinuation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Increases CSBMs per week (MD <q>1.37</q>) and SBMs per week (MD <q>1.97</q>).</li><li>- May lead to a large increase in responder rates (RR <q>3.14</q>).</li><li>- Patients are <q>3 times</q> more likely to have diarrhea leading to discontinuation (RR <q>3.35</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Plecanatide</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 9:</b> <u>Recommends</u> the use of plecanatide.</li><li>- <b>Strength:</b> Strong</li><li>- <b>Certainty of Evidence:</b> Moderate</li></ul>
                
        <details>
            <summary><strong>Mechanism & Dosing</strong></summary>
            <div>
                <ul><li>- Acts on <b>guanylate cyclase-C</b>.</li><li>- Dose for CIC and IBS-C: <q>3 mg</q> daily.</li><li>- Can be taken with or without food.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy & Side Effects</strong></summary>
            <div>
                <ul><li>- Increases CSBMs per week (MD <q>1.1</q>) and SBMs per week (MD <q>1.66</q>).</li><li>- Increased responder rates (RR <q>1.78</q>).</li><li>- Higher rates of diarrhea leading to discontinuation (RR <q>5.39</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>5-HT4 Agonist</strong></summary>
            <div>
                <ul><li>- Recommended for patients who do not respond to OTC agents.</li></ul>
                
        <details>
            <summary><strong>Prucalopride</strong></summary>
            <div>
                <ul><li>- <b>Recommendation 10:</b> <u>Recommends</u> the use of prucalopride.</li><li>- <b>Strength:</b> Strong</li><li>- <b>Certainty of Evidence:</b> Moderate</li></ul>
                
        <details>
            <summary><strong>Mechanism & Dosing</strong></summary>
            <div>
                <ul><li>- A selective, high-affinity <b>serotonin type 4 (5-HT4) agonist</b>.</li><li>- Recommended dose is <q>2 mg</q> once daily.</li><li>- Dose is reduced to <q>1 mg</q> daily in individuals with severe renal impairment (creatinine clearance <q><30 mL/min</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Side Effects & Safety</strong></summary>
            <div>
                <ul><li>- Most frequent side effects are headache, abdominal pain, nausea, and diarrhea.</li><li>- These side effects are generally transient, occurring within the first week and resolving in a few days.</li><li>- Label cautions about unusual changes in mood/behavior and suicidal ideation, but a causal link is unclear.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Resulted in an increased number of CSBMs per week (MD <q>0.96</q>).</li><li>- Responder rates were higher in the prucalopride group (RR <q>2.37</q>).</li><li>- Improved quality of life scores (PAC-QOL).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
